NEW YORK, Nov. 9, 2016 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities Arrowhead Pharmaceuticals, Inc. ("Arrowhead" or the "Company") (NASDAQ: ARWR). Such investors are advised to contact Peretz Bronstein or his investor relations analyst Yael Hurwitz at email@example.com or 212-697-6484.
The investigation concerns whether Arrowhead and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
On November 8, 2016, post-market, Arrowhead revealed that the United States Food & Drug Administration will be placing a clinical hold on Arrowhead's Heparc-2004 clinical study of ARC-520. Arrowhead believes this hold to be the result of deaths at the highest dose of an ongoing non-human primate toxicology study, and said that these deaths are currently being investigated. Following this news, Arrowhead stock dropped $6.11 per share, and closed at $4.45 per share on November 9, 2016.
If you are aware of any facts relating to this investigation, or purchased Arrowhead shares, you can assist this investigation by visiting the firm's site: http://www.bgandg.com/arwr. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484 or via email firstname.lastname@example.org. Those who inquire by e-mail are encouraged to include their mailing address, email and telephone number.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | email@example.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert-bronstein-gewirtz--grossman-llc-announces-investigation-of-arrowhead-pharmaceuticals-inc-arwr-300359990.html
SOURCE Bronstein, Gewirtz & Grossman, LLC